Corneal Nerve Loss in Patients with Acute Ischemic Stroke: A Surrogate Marker for Poor Pial Collaterals

Adnan Khan  
Weill Cornell Medicine-Qatar

Ajay Menon  
Weill Cornell Medicine-Qatar

Naveed Akhtar  
Hamad Medical Corporation

Saadat Kamran  
Hamad Medical Corporation

Ahmad Muhammad  
Hamad Medical Corporation

Georgios Ponirakis  
Weill Cornell Medicine-Qatar

Hoda Gad  
Weill Cornell Medicine-Qatar

Ioannis Petropoulos  
Weill Cornell Medicine-Qatar

Faisal Wadiwala  
Hamad Medical Corporation

Blessy babu  
Hamad Medical Corporation

Adeeb Narangoli  
Weill Cornell Medicine-Qatar

Pablo Bermejo  
John Hunter Hospital

Hanadi Al Hamad  
Rumailah Hospital, Hamad Medical Corporation

Marwan Ramadan  
Rumailah Hospital, Hamad Medical Corporation

Peter Woodruff  
Hamad Medical Corporation

Mark Santos  
Hamad Medical Corporation

Maher Saqqur
University of Toronto at Mississauga

Ashfaq Shuaib
University of Alberta

Rayaz A. Malik (ram2045@qatar-med.cornell.edu)
Weill Cornell Medicine-Qatar

Research Article

Keywords: Corneal Nerve Fibre, Corneal Confocal Microscopy, Corneal Endothelial Cell Pial Collateral, Stroke

DOI: https://doi.org/10.21203/rs.3.rs-558220/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: In patients with ischemic stroke, pial collaterals play a key role in limiting neurological disability by maintaining blood flow to ischemic penumbra. We hypothesized that patients with poor pial collateral status will have greater corneal nerve and endothelial cell abnormalities.

Method: 35 patients with acute ischemic stroke secondary to middle cerebral artery occlusion with poor (n=12) and moderate/good (n=23) pial collaterals and 35 healthy controls underwent corneal confocal microscopy and quantification of corneal nerve and endothelial cell morphology.

Results: In patients with MCA stroke, corneal nerve fibre length (CNFL) (P=0.000), density (CNFD) (P=0.025) and branch density (CNBD) (P=0.002) were lower compared to controls. Age, BMI, cholesterol, triglycerides, HDL, LDL, systolic blood pressure, NIHSS and endothelial cell parameters did not differ but mRS was higher (p=0.023) and CNFL (p=0.026) and CNBD (p=0.044) were lower in patients with poor compared to moderate-good collaterals. CNFL and CNBD distinguished subjects with poor from good pial collaterals with an AUC of 72% (95% CI: 53-92%) and 71% (95% CI: 53-90%), respectively.

Conclusion: Corneal nerve loss is greater in patients with poor compared to good pial collaterals and may act as a surrogate marker for pial collateral status in patients with ischemic stroke.

Background

Stroke is a major cause of disability and the second leading cause of death\(^1\). Ischemic stroke typically occurs following occlusion of a cerebral artery due to in situ thrombosis or an embolus from the heart or neck vessels\(^2\). Several studies have shown that the leptomeningeal collateral circulation, or pial collateral status determines the neurological outcomes following acute ischemic stroke\(^3\). Indeed, patients with poor pial collaterals sustain larger infarcts, respond poorly to reperfusion, have increased risk for and severity of intracerebral hemorrhage and suffer increased morbidity and mortality\(^3\)–\(^6\).

There is considerable variability in the pial collateral status amongst patients with acute ischemic stroke\(^7\),\(^8\). Along with genetics factors, several modifiable risk factors such as hypertension\(^9\), metabolic syndrome, hyperuricemia, age\(^10\), smoking\(^11\) and hyperglycemia\(^12\) are associated with poor collaterals. Animal studies have shown that “rarefaction of collaterals” is associated with multiple cardiovascular risk factors\(^13\). Additionally, MR imaging has also shown that the presence of white matter hyperintensities is associated with a poor pial collateral circulation\(^14\) and their severity is associated with poor outcomes after stroke\(^15\).

Corneal confocal microscopy (CCM) is a rapid non-invasive ophthalmic imaging technique that has been used to demonstrate axonal loss in patients with impaired glucose tolerance\(^16\), diabetes\(^17\),\(^18\), and other peripheral neuropathies\(^19\). Recent studies have also demonstrated a significant reduction in corneal nerves\(^20\)–\(^22\) and abnormalities in endothelial cells in patients with TIA\(^23\) and acute ischemic stroke\(^22\). We
have also shown that corneal nerve loss is associated with age, HbA$_1c$, lipids and blood pressure$^{18}$ and the presence of white matter hyperintensities$^{24}$ in patients with acute ischemic stroke.

This study aimed to assess whether corneal nerve and endothelial cell abnormalities could act as surrogate markers of the pial collateral status in patients with acute ischemic stroke.

**Results**

Thirty-five patients with acute MCA stroke were age-matched with thirty-five healthy controls (51.54 ± 10.50 vs 52.82 ± 17.88 yrs., $p = 0.717$). The systolic blood pressure (144.71 ± 24.44 vs 132.31 ± 16.06, $P = 0.014$) was higher and HDL (0.88 ± 0.21 vs 1.32 ± 0.37, $P = 0.000$) was lower in patients with stroke compared to controls.

**Clinical, Metabolic and Neurological Disability According to Pial Collateral Status**

Patients with MCA stroke were classified into those with poor (n = 12) and moderate-good (n = 23) pial collaterals. Age (52.42 ± 8.39 vs 51.09 ± 11.60, $p = 0.797$), BMI (27.88 ± 3.40 vs 27.73 ± 4.39, $p = 0.919$), total cholesterol (4.76 ± 1.26 vs 4.92 ± 0.97, $p = 0.694$), triglycerides (1.59 ± 0.75 vs 1.68 ± 0.77, $p = 0.632$), LDL (3.14 ± 1.00 vs 3.28 ± 0.89, $p = 0.686$), HDL (0.91 ± 0.29 vs 0.87 ± 0.15, $p = 0.626$), systolic blood pressure (145.00 ± 20.32 vs 144.57 ± 26.76, $p = 0.961$) and HbA$_1c$ (7.29 ± 3.69 vs 6.02 ± 1.16, $p = 0.294$) did not differ significantly between patients with poor compared to moderate-good pial collaterals (Table 1).
Table 1
Demographic, metabolic, and clinical characteristics of healthy controls and participants with acute ischemic stroke with moderate-good and poor pial collaterals expressed as mean ± SD. * Statistically significant differences between groups.

| Parameters                        | All Control (n = 35) | All stroke (n = 35) | P-value | Moderate-Good collateral (n = 23) | Poor collateral (n = 12) | P-value |
|-----------------------------------|----------------------|---------------------|---------|----------------------------------|------------------------|---------|
| Age (years)                      | 52.82 ± 17.88        | 51.54 ± 10.50       | 0.717   | 51.09 ± 11.60                    | 52.42 ± 8.39          | 0.797   |
| BMI (kg/m²)                      | 27.89 ± 5.06         | 27.79 ± 4.01        | 0.926   | 27.73 ± 4.39                     | 27.88 ± 3.40          | 0.919   |
| Systolic blood pressure (mmHg)   | 132.31 ± 16.06       | 144.71 ± 24.44      | 0.014*  | 144.57 ± 26.76                   | 145.00 ± 20.32        | 0.961   |
| HbA₁c (%)                        | 5.59 ± 0.42          | 6.45 ± 2.37         | 0.055   | 6.02 ± 1.16                      | 7.29 ± 3.69           | 0.294   |
| Total cholesterol (mmol/l)       | 4.95 ± 0.87          | 4.86 ± 1.07         | 0.715   | 4.92 ± 0.97                      | 4.76 ± 1.26           | 0.694   |
| Triglycerides (mmol/l)           | 1.60 ± 1.48          | 1.65 ± 0.75         | 0.887   | 1.68 ± 0.77                      | 1.59 ± 0.75           | 0.632   |
| LDL (mmol/l)                     | 2.98 ± 0.72          | 3.23 ± 0.92         | 0.251   | 3.28 ± 0.89                      | 3.14 ± 1.00           | 0.686   |
| HDL (mmol/l)                     | 1.32 ± 0.37          | 0.88 ± 0.21         | 0.000*  | 0.87 ± 0.15                      | 0.91 ± 0.29           | 0.626   |
| mRS at admission                 | NA                   | 2.15 ± 1.48         | NA      | 1.68 ± 1.25                      | 3.00 ± 1.54           | 0.023*  |
| mRS 90 days after discharge      | NA                   | 1.30 ± 1.46         | NA      | 0.83 ± 1.04                      | 2.22 ± 1.79           | 0.067   |
| NIHSS at admission               | NA                   | 12.09 ± 6.30        | NA      | 10.68 ± 5.96                     | 14.67 ± 6.31          | 0.065   |
| NIHSS 90 days after discharge    | NA                   | 5.23 ± 5.60         | NA      | 3.76 ± 4.72                      | 8.00 ± 6.32           | 0.120   |

The modified Rankin Scale (mRS) at admission (3.00 ± 1.54 vs 1.68 ± 1.25, p = 0.023) was significantly higher in patients with poor compared to moderate-good pial collaterals. Although not significant, the mRS at discharge (mRS: 2.22 ± 1.79 vs 0.83 ± 1.04, p = 0.067), and the National Institute of Health Stroke Scale (NIHSS) at admission (14.67 ± 6.31 vs 10.68 ± 5.96, p = 0.065) and at discharge (8.00 ± 6.32 vs 3.76 ± 4.72, p = 0.120) were higher in patients with poor compared to moderate-good pial collaterals (Table 1).
Corneal Nerve and Endothelial cell Parameters in Patients with Acute Ischemic Stroke Compared to Controls

CNFL (19.22 ± 5.78 vs 24.03 ± 5.21, p = 0.000), CNFD (30.45 ± 8.41 ± 34.62 ± 6.70, p = 0.025) and CNBD (64.20 ± 35.70 vs 97.31 ± 48.21, p = 0.002) were significantly lower in patients with MCA stroke compared to controls (Fig. 1, Table 2). There was no significant difference in corneal endothelial cell density (ECD) (2876.61 ± 374.58 vs 2924.95 ± 229.20, p = 0.790), endothelial cell area (ECA) (308.91 ± 41.19 vs 300.41 ± 21.57, p = 0.683), endothelial cell perimeter (ECP) (64.64 ± 4.33 vs 63.75 ± 2.60, p = 0.763), endothelial cell polymegathism (49.62 ± 3.61 vs 52.38 ± 5.87, p = 0.112) or pleomorphism (27.25 ± 4.64 vs 26.95 ± 5.10, p = 0.864) between patients with stroke compared to controls (Fig. 2, Table 2).
Table 2

Corneal nerve and endothelial cell measures comparing controls to patients with acute ischemic stroke and between patients with moderate-good and poor collaterals expressed as mean ± SD. * Statistically significant differences between groups tested using t-test at p ≤ 0.05 (data in bold).

| Corneal Nerve Parameters | Control (n = 35) | All stroke (n = 35) | P-value | Moderate-Good collateral (n = 23) | Poor collateral (n = 12) | P-value |
|--------------------------|-----------------|---------------------|---------|----------------------------------|--------------------------|---------|
| CNFL, mm/mm²             | 24.03 ± 5.21    | 19.22 ± 5.78        | 0.000*  | 20.76 ± 5.22                    | 16.26 ± 5.84             | 0.026*  |
| CNFD, no/mm²             | 34.62 ± 6.70    | 30.45 ± 8.41        | 0.025*  | 31.70 ± 6.85                    | 28.07 ± 10.74            | 0.231   |
| CNBD, no/mm²             | 97.31 ± 48.21   | 64.20 ± 35.70       | 0.002*  | 72.89 ± 35.89                   | 47.53 ± 30.04            | 0.044*  |

| Endothelial Cell Parameters | Control (n = 16) | All stroke (n = 17) | P-value | Moderate-Good collateral (n = 11) | Poor collateral (n = 6) | P-value |
|-----------------------------|-----------------|---------------------|---------|----------------------------------|--------------------------|---------|
| ECD, cells/mm²             | 2924.95 ± 229.20 | 2876.61 ± 374.58   | 0.790   | 2974.11 ± 346.57                | 2697.86 ± 386.66        | 0.152   |
| ECA, µm²                   | 300.41 ± 21.57  | 308.91 ± 41.19      | 0.683   | 297.71 ± 36.6                   | 329.44 ± 44.37          | 0.133   |
| ECP, µm                    | 63.75 ± 2.60    | 64.64 ± 4.33        | 0.763   | 63.54 ± 3.9                     | 66.67 ± 4.68            | 0.160   |
| EC Polymegathism, %        | 52.38 ± 5.87    | 49.62 ± 3.61        | 0.112   | 49.95 ± 4.14                    | 49.00 ± 2.6             | 0.621   |
| EC Pleomorphism, %          | 26.95 ± 5.10    | 27.25 ± 4.64        | 0.864   | 26.68 ± 5.43                    | 28.28 ± 2.82            | 0.515   |

**Corneal Nerve and Endothelial cell Parameters in Patients with Poor Compared to Good Pial Collaterals**

CNFL (16.26 ± 5.84 vs 20.76 ± 5.22, p = 0.026) and CNBD (47.53 ± 30.04 vs 72.89 ± 35.89, p = 0.044) were significantly lower with no difference in CNFD (p = 0.231) between patients with poor compared to moderate-good collaterals (Table 2, Fig. 3). There was no significant ECD (2697.86 ± 386.66 vs 2974.11 ± 346.57, p = 0.152), ECA (329.44 ± 44.37 vs 297.71 ± 36.6, p = 0.133), ECP (66.67 ± 4.68 vs 63.54 ± 3.9, p = 0.160), endothelial cell polymegathism (49.00 ± 2.6 vs 49.95 ± 4.14, p = 0.621) or pleomorphism (28.28 ±
2.82 vs 26.68 ± 5.43, p = 0.515) between patients with poor compared to moderate-good collaterals (Fig. 2, Table 2).

**Diagnostic accuracy for distinguishing Poor from Moderate-Good Collateral Patients**

Table 3 and Fig. 4 show the diagnostic accuracy of CCM measures for identifying patients with poor compared to moderate-good collaterals. CNFL and CNBD distinguished subjects with poor from good collaterals with 72% AUC (95% CI: 53–92%) and 71% AUC (95% CI: 53–90%), respectively. Using an abnormal cutoff of CNFL ≤ 16 mm/mm² the sensitivity and specificity were 96% and 58%, respectively, and using an abnormal cutoff of CNBD ≤ 62 mm/mm² the sensitivity and specificity were 65% and 75% according to Youden index, respectively.

| CCM Parameters | AUC % (95% CI) | P value | Cutoff point | Sensitivity (%) | Specificity (%) |
|----------------|----------------|---------|--------------|----------------|-----------------|
| CNFL, mm/mm²   | 71 (53–92)     | = 0.034 | ≤ 17         | 87             | 42              |
| CNBD, branches/mm² | 71 (53–90) | = 0.040 | ≤ 43         | 74             | 42              |

**Discussion**

In this translational study, we show evidence of corneal nerve loss in patients with acute MCA stroke compared to healthy controls, which agrees with our recent studies showing corneal nerve loss in patients with TIA, acute, and recurrent stroke. Moreover, we show that corneal nerve loss was greater and there was good diagnostic accuracy for differentiating patients with poor compared to moderate-good pial collaterals, despite comparable blood pressure, lipids and HbA1c. Although we have previously shown corneal endothelial cell abnormalities in patients with TIA and stroke, the current study showed no differences between patients with MCA stroke and controls or between patients with good compared to poor pial collaterals.

Pial collateral status can only be ascertained after ischemic stroke due to large vessel occlusion. White matter hyperintensities (WMH) predict poor stroke outcomes 90 days after thrombectomy. In a recent study, the presence of WMH was associated with greater cerebrovascular dysfunction in patients with large vessel occlusion and favorable outcomes in the ASPECT score in those without WMH. The severity of WMH is associated with endothelial dysfunction, and poor pial collateral circulation. Many
of the risk factors and comorbidities associated with WMHs have also been associated with poor pial collateral status. WMH increase with age\textsuperscript{29}, hypertension\textsuperscript{30,31} and diabetes\textsuperscript{32,33} and may improve with antiplatelet therapy\textsuperscript{34} and improved management of hypertension\textsuperscript{30,31} and diabetes\textsuperscript{32,33}. These same risk factors have also been related to corneal nerve degeneration\textsuperscript{35} and indeed improvement in blood pressure, lipids and glycemic control is associated with corneal nerve regeneration\textsuperscript{36,37}. Recently we showed that CCM may act as a surrogate imaging marker for the presence and severity of WMHs in patients with acute ischemic stroke\textsuperscript{24}.

CCM has emerged as a powerful non-invasive ophthalmic imaging endpoint to identify corneal nerve loss in patients with multiple sclerosis\textsuperscript{38}, Parkinson’s disease\textsuperscript{39}, dementia\textsuperscript{40} and patients with acute ischemic stroke\textsuperscript{20} and recurrent stroke\textsuperscript{21}. We now show that CCM identifies greater corneal nerve loss in patients with poor compared to moderate/good pial collaterals. This ophthalmic imaging method may act as a surrogate imaging marker for poor pial collaterals and allow the identification of patients who require greater risk factor reduction and more urgent reperfusion for ischemic stroke. Indeed, in the present study patients with poor pial collaterals had a higher mRS and a previous study showed a larger infarct volume and higher mRS and NIHSS in patients with worse pial collateral scores\textsuperscript{41}.

Limitations of the current study include the moderate sample size and the assessment of only patients with moderate disability who could undergo CCM. However, our study broadens the clinical utility of CCM in patients with neurodegenerative disease and in the assessment of patients with ischemic stroke. These data warrant larger studies utilising CCM in patients with or at risk of ischemic stroke.

**Materials And Methods**

Thirty-five patients with middle cerebral artery occlusion and 35 age-matched healthy control participants were recruited. Exclusion criteria included patients with stroke secondary to non-vascular disorder, intracerebral hemorrhage, a known history of ocular trauma or surgery, high refractive error, and glaucoma.

Acute ischemic stroke was confirmed clinically and radiologically using American Heart Association (AHA) criteria\textsuperscript{42}. The pial collateral status was established using multi-modal/dynamic CTA according to the criteria of Tan et al.\textsuperscript{43}. The ordinal collateral score ranges from 0 to 3: 0= absent collateral supply to the occluded MCA territory (defined as “poor”), 1= collateral supply filling $\leq 50\%$ but $>0\%$ of the occluded MCA territory, 2= collateral supply filling $>50\%$ but $<100\%$ of the occluded MCA territory and 3= 100\% collateral supply of the occluded MCA territory (defined as “good”).

Clinical and demographic data along with blood pressure, HbA\textsubscript{1c} and lipid profile were obtained at admission. The National Institutes of Health Stroke Scale (NIHSS)\textsuperscript{44} and modified Rankin Scale (mRS)\textsuperscript{45} was obtained for all patients at admission and at discharge from hospital.
Corneal Confocal Microscopy

All patients underwent CCM (Heidelberg Retinal Tomograph III Rostock Cornea Module; Heidelberg Engineering GmbH, Heidelberg, Germany). CCM uses a 670 nm wavelength helium neon diode laser, which is a class I laser and therefore does not pose any ocular safety hazard. A ×63 objective lens with a numeric aperture of 0.9 and a working distance, relative to the applanating cap (TomoCap; Heidelberg Engineering GmbH) of 0.0 to 3.0 mm, is used. The size of each 2-dimensional image produced is 384×384 pixels with a 15°×15° field of view and 10 μm/pixel transverse optical resolutions. To perform the CCM examination, local anesthetic (0.4% benoxinate hydrochloride; Chauvin Pharmaceuticals, Chefaro, United Kingdom) was used to anesthetize both eyes, and Viscotears (Carbomer 980, 0.2%, Novartis, United Kingdom) was used as the coupling agent between the cornea and the cap. Patients were asked to fixate on an outer fixation light throughout the CCM scan and a CCD camera was used to correctly position the cap onto the cornea. The examination took approximately 10 minutes for both eyes. The examiners captured images of the central sub-basal nerve plexus using the section mode. On the basis of depth, contrast, focus, and position, 6 images per patient were selected.

All CCM images were manually analysed using validated, purpose-written software. Corneal nerve fiber density (CNFD: total number of nerves /mm²), corneal nerve branch density (CNBD: number of branches emanating from major nerve trunks /mm²), corneal nerve fiber length (CNFL: total length of all nerve fibers and branches mm/mm²) and inferior whorl length (IWL: total length of all nerve fibers in inferior whorl area mm/mm²) were analyzed using CCMetrics (M. A. Dabbah, ISBE, University of Manchester, Manchester, United Kingdom). Corneal endothelial cell images were analyzed using the Corneal Endothelium Analysis System (CEAS), an automated image analysis system. Endothelial cell density (ECD, cells/mm²), endothelial cell area (ECA, µm²), endothelial cell perimeter (ECP, µm), endothelial cell polymegathism (%) and endothelial cell pleomorphism (%) were quantified. Polymegathism was defined as the standard deviation of the cell area divided by the mean cell area, while pleomorphism was defined as the hexagonality coefficient. Adequate corneal endothelial cells images were available in seventeen patients with poor (n=6) and moderate-good (n=11) collaterals and sixteen healthy controls.

Statistical Analysis

All statistical analyses were performed using IBM SPSS Statistics software Version 25. Normality of the data was assessed using the Shapiro-Wilk test and by visual inspection of the histogram and a normal Q-Q plot. Data are expressed as mean ± standard deviation (SD). Mann Whitney test (for non-normally distributed variables) and t-test (for normally distributed variables) were performed to find the differences between two groups. Receiver operating characteristic (ROC) curve analysis was performed for corneal nerve parameters to identify patients with poor compared to moderate-good collateral status.

Declarations
Funding

Supported by Qatar National Research Fund Grant BMRP20038654. The funders had no role in study design, data collection and analysis, decision to publish, or publish, or preparation of the manuscript.

Conflict of Interest/Competing Interests

The authors declare that they have no conflict of interest.

Ethics Approval

This study adhered to the tenets of the declaration of Helsinki and was approved by the Institutional Review Board of Weill Cornell Medicine (15–00021) and Hamad General Hospital (15304/15).

Consent to participate

Informed, written consent was obtained from all patients/guardians before participation in the study.

Consent for publication

Written consent was obtained from all patients/guardians for publications.

Availability of data and material

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author’ contributions

Conceptualization: AS, RAM and AK; Methodology: AS, RAM, SK and AK; Software: AK & AM; Validation: AK, AM; Formal Analysis: AK, AM; Investigation: AK, GP, INP, HG, NA, AMN, FW, BB, PGB, HAH, MR, PW, MS, M Sant, SK; Resources: AS and NA; Data Curation: AK, MS; Writing – Original Draft Preparation: AK; Writing Review & Editing: AS and RAM; Visualization: MS; Supervision: AS; Project Administration: AS; Funding Acquisition: AS and RAM.

References
1. Virani, S. S. *et al.* Heart disease and stroke statistics—2020 update: a report from the American Heart Association. *Circulation*, E139-E596 (2020).

2. Adams, H. P. Jr *et al.* Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke.* **24**, 35–41 (1993).

3. Jung, S. *et al.* Relevance of the cerebral collateral circulation in ischaemic stroke: time is brain, but collaterals set the pace. *Swiss Med. Wkly.* **147**, w14538 (2017).

4. Leng, X. *et al.* Impact of collateral status on successful revascularization in endovascular treatment: a systematic review and meta-analysis. *Cerebrovasc Dis.* **41**, 27–34 (2016).

5. Flores, A. *et al.* Poor collateral circulation assessed by multiphase computed tomographic angiography predicts malignant middle cerebral artery evolution after reperfusion therapies. *Stroke.* **46**, 3149–3153 (2015).

6. Christoforidis, G. *et al.* Predictors of hemorrhage following intra-arterial thrombolysis for acute ischemic stroke: the role of pial collateral formation. *AJNR Am J Neuroradiol.* **30**, 165–170 (2009).

7. Malhotra, K. & Liebeskind, D. S. Collaterals in ischemic stroke. *Brain Hemorrhages.* 1, 6–12 (2020).

8. Faber, J. E. *et al.* Genetic and environmental contributions to variation in the posterior communicating collaterals of the circle of Willis. *Transl Stroke Res.* **10**, 189–203 (2019).

9. Fujita, K. *et al.* Detrimental effect of chronic hypertension on leptomeningeal collateral flow in acute ischemic stroke. *Stroke.* **50**, 1751–1757 (2019).

10. Menon, B. K. *et al.* Leptomeningeal collaterals are associated with modifiable metabolic risk factors. *Ann Neurol.* **74**, 241–248 (2013).

11. Nannoni, S. *et al.* Determining factors of better leptomeningeal collaterals: a study of 857 consecutive acute ischemic stroke patients. *J Neurol.* **266**, 582–588 (2019).

12. van Seeters, T., Biessels, G. J., Kappelle, L. J., van der Graaf, Y. & Velthuis, B. K. Determinants of leptomeningeal collateral flow in stroke patients with a middle cerebral artery occlusion. *Neuroradiology.* **58**, 969–977 (2016).

13. Moore, S. M., Zhang, H., Maeda, N., Doerschuk, C. M. & Faber, J. E. Cardiovascular risk factors cause premature rarefaction of the collateral circulation and greater ischemic tissue injury. *Angiogenesis.* **18**, 265–281 (2015).

14. Mark, I. *et al.* Leukoaraiosis and collateral blood flow in stroke patients with anterior circulation large vessel occlusion. *J Neurointerv Surg* (2020).

15. Huo, L. *et al.* Impact of leukoaraiosis severity on the association of outcomes of mechanical thrombectomy for acute ischemic stroke: a systematic review and a meta-analysis. *J Neurol,* 1–9 (2020).

16. Asghar, O. *et al.* Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. *Diabetes Care.* **37**, 2643–2646 (2014).
17. Petropoulos, I. N. et al. Rapid automated diagnosis of diabetic peripheral neuropathy with in vivo corneal confocal microscopy. *Invest Ophthalmol Vis Sci.* **55**, 2071–2078 https://doi.org/10.1167/iovs.13-13787 (2014).

18. Ferdousi, M. et al. Diagnosis of neuropathy and risk factors for corneal nerve loss in type 1 and type 2 diabetes: A corneal confocal microscopy study. *Diabetes Care.* **44**, 150–156 (2021).

19. Tavakoli, M. & Malik, R. A. Corneal confocal microscopy: A novel non-invasive technique to quantify small fibre pathology in peripheral neuropathies. *J Vis Exp.* 1–7 https://doi.org/10.3791/2194 (2011).

20. Khan, A. et al. Corneal confocal microscopy detects corneal nerve damage in patients admitted with acute ischemic stroke. *Stroke.* **48**, 3012–3018 https://doi.org/10.1161/STROKEAHA.117.018289 (2017).

21. Khan, A. et al. Corneal confocal microscopy identifies greater corneal nerve damage in patients with a recurrent compared to first ischemic stroke. *PloS One.* **15**, e0231987 (2020).

22. Khan, A. et al. Corneal confocal microscopy detects a reduction in corneal endothelial cells and nerve fibres in patients with acute ischemic stroke. *Sci Rep.* **8**, 17333 (2018).

23. Gad, H. et al. Corneal nerve and endothelial cell damage in patients with transient ischemic attack and minor ischemic stroke. PloS One 14, e0213319, doi:0.1371/journal.pone.0213319(2019).

24. Kamran, S. et al. Cornea: A window to white matter changes in stroke; corneal confocal microscopy a surrogate marker for the presence and severity of white matter hyperintensities in ischemic stroke. *J Stroke Cerebrovasc Dis* 1–8(2020).

25. Griessenauer, C. J. et al. Effects of white matter hyperintensities on 90-Day functional outcome after large vessel and non-large vessel stroke. *Cerebrovasc Dis.* **49**, 1–8 (2020).

26. Mutzenbach, J. S. et al. Severe leukoaraiosis is associated with poor outcome after successful recanalization of M1 middle cerebral artery occlusion strokes. *Cerebrovasc Dis.* **49**, 253–261 (2020).

27. Regenhardt, R. W. et al. White matter acute infarct volume after thrombectomy for anterior circulation large vessel occlusion stroke is associated with long term outcomes. *J Stroke Cerebrovasc Dis.* **30**, 105567 (2020).

28. Young, V. G., Halliday, G. M. & Kril, J. J. Neuropathologic correlates of white matter hyperintensities. *Neurology.* **71**, 804–811 (2008).

29. Smith, E. E. et al. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke.* **48**, e44–e71 https://doi.org/10.1161/STR.0000000000000116 (2017).

30. de Leeuw, F. E. et al. Hypertension and cerebral white matter lesions in a prospective cohort study. *Brain.* **125**, 765–772 https://doi.org/10.1093/brain/awf077 (2002).

31. Dufouil, C. et al. Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI Cohort. *Neurology.* **56**, 921–926 https://doi.org/10.1212/wnl.56.7.921 (2001).
32. McNay, E. C. The impact of recurrent hypoglycemia on cognitive function in aging. *Neurobiol Aging.* 26 Suppl (1), 76–79 https://doi.org/10.1016/j.neurobiolaging.2005.08.014 (2005).

33. Geijtselaers, S. L. C. *et al.* The Role of Hyperglycemia, Insulin Resistance, and Blood Pressure in Diabetes-Associated Differences in Cognitive Performance-The Maastricht Study. *Diabetes Care.* 40, 1537–1547 https://doi.org/10.2337/dc17-0330 (2017).

34. Gorelick, P. B. *et al.* Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. *Stroke.* 42, 2672–2713 https://doi.org/10.1161/STR.0b013e3182299496 (2011).

35. Ponirakis, G. *et al.* Hypertension Contributes to Neuropathy in Patients With Type 1 Diabetes. *Am J Hypertens.* 32, 796–803 https://doi.org/10.1093/ajh/hpz058 (2019).

36. Tavakoli, M. *et al.* Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. *Diabet Med.* 28, 1261–1267 https://doi.org/10.1111/j.1464-5491.2011.03372.x (2011).

37. Azmi, S. *et al.* Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation. *Diabetologia.* 62, 1478–1487 https://doi.org/10.1007/s00125-019-4897-y (2019).

38. Petropoulos, I. N. *et al.* Corneal confocal microscopy: an imaging endpoint for axonal degeneration in multiple sclerosis. *Invest Ophthalmol Vis Sci.* 58, 3677–3681 (2017).

39. Lim, S. H. *et al.* Corneal confocal microscopy detects small fibre neurodegeneration in Parkinson's disease using automated analysis. *Sci Rep.* 10, 1–7 (2020).

40. Ponirakis, G. *et al.* Association of corneal nerve fiber measures with cognitive function in dementia. *Ann Clin Transl Neurol.* 6, 689–697 (2019).

41. Christoforidis, G. A., Mohammad, Y., Kehagias, D., Avutu, B. & Slivka, A. P. Angiographic assessment of pial collaterals as a prognostic indicator following intra-arterial thrombolysis for acute ischemic stroke. *AJNR Am J Neuroradiol.* 26, 1789–1797 (2005).

42. Powers, W. J. *et al.* 2018 Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* 49, e46-e110, doi:10.1161/STROKEAHA.119.026917 (2018).

43. Tan, I. *et al.* CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. *AJNR Am J Neuroradiol.* 30, 525–531 (2009).

44. Brott, T. *et al.* Measurements of acute cerebral infarction: a clinical examination scale. *Stroke.* 20, 864–870 (1989).

45. Wilson, J. L. *et al.* Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. *Stroke.* 33, 2243–2246 (2002).

46. Vagenas, D. *et al.* Optimal image sample size for corneal nerve morphometry. *Optom Vis Sci.* 89, 812–817 https://doi.org/10.1097/OPX.0b013e31824ee8c9 (2012).
47. Al-Fahdawi, S. et al. A fully automated cell segmentation and morphometric parameter system for quantifying corneal endothelial cell morphology. *Comput Methods Programs Biomed.* **160**, 11–23 (2018).

**Figures**

![Dot plots of corneal nerve fiber parameters](image)

**Figure 1**

Dot plots of corneal nerve fiber parameters: (A) corneal nerve fiber length (CNFL), (B) corneal nerve fiber density (CNFD), (C) and corneal nerve branch density (CNBD), in controls, all stroke and stroke participants with poor compared to moderate-good collaterals.
Figure 2

Dot plots of corneal endothelial cell (EC) parameters: (A) endothelial cell density, (B) endothelial cell area, (C) endothelial cell perimeter, (D) endothelial cell polymegathism (E) and endothelial cell pleomorphism in patients with poor compared to moderate-good collaterals.
Figure 3

Corneal nerve morphology in a healthy control (A), patient with moderate-good pial collaterals (B) and patient with poor collaterals (C).

Figure 4

ROC analysis showing the area under the curve for corneal nerve fiber length and branch density.